QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=4DA2ED7BBCCA5CAD0216612FD8B5B135;jsessionid=402CD09D12027F9CEE86DE7EF9FFC046;jsessionid=C1BBDD0CBC8923CE4F9AFF45C3B8347C;jsessionid=A651D96718FA2717605410C365B16C06;jsessionid=80724429343A228AEB62730113E25FAF;jsessionid=87D50AD7994C004A6A11E3502B48522F;jsessionid=CCEDD60A81C88054056332882336FE42;jsessionid=87F9200C92D03D551D839C14F36A3A3C;jsessionid=7CF3C21CE3326A0A8F74D1D13816A8B4;jsessionid=159D18222C5F80D3A8730AA0C4E4084C (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=4DA2ED7BBCCA5CAD0216612FD8B5B135;jsessionid=402CD09D12027F9CEE86DE7EF9FFC046;jsessionid=C1BBDD0CBC8923CE4F9AFF45C3B8347C;jsessionid=A651D96718FA2717605410C365B16C06;jsessionid=80724429343A228AEB62730113E25FAF;jsessionid=87D50AD7994C004A6A11E3502B48522F;jsessionid=CCEDD60A81C88054056332882336FE42;jsessionid=87F9200C92D03D551D839C14F36A3A3C;jsessionid=7CF3C21CE3326A0A8F74D1D13816A8B4;jsessionid=159D18222C5F80D3A8730AA0C4E4084C